CIK 0001485003
CARM Carisma Therapeutics Inc.
Insider trading from SEC Form 4. Last filing Oct 8, 2025. Close $0.00 on Oct 9, 2026, +400% from the 52-week low and -100% from the high.
In brief
Carisma Therapeutics Inc. (CARM) has 8 SEC Form 4 filings on file from 4 insiders, the latest filed on Oct 8, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
2 open-market trades have been scored at CARM. The newest: Michael Klichinsky (Chief Scientific Officer) sold $14k of stock on Oct 7, 2025, filed Oct 8, 2025, scored 20 (weak). The largest of the 2 shown: Michael Klichinsky (Chief Scientific Officer) sold $124k on Oct 1, 2025, scored 45 (moderate).
2 Form 144 notices of planned sales are on file, the latest filed Oct 6, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Carisma Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Michael Klichinsky Chief Scientific Officer sell | $14k 56,982 shares | -100% | - | |
| 45Moderate | Michael Klichinsky Chief Scientific Officer sell | $124k 484,347 shares | -100% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 6, 2025 | MICHAEL KLICHINSKY OFFICER | 56,982 0.14% of outstanding | $14k | Oct 7, 2025 | $124k |
| Sep 30, 2025 | MICHAEL KLICHINSKY Officer | 484,347 1.16% of outstanding | $134k | Sep 30, 2025 | none |
Transactions
Every row filed, 12 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 7, 2025 | Michael Klichinsky Chief Scientific Officer | MOption exercise Common Stock | +56,982 | $0.11 | $6,268 | 56,982 | Oct 8, 2025 |
| Oct 7, 2025 | Michael Klichinsky Chief Scientific Officer | SOpen-market sale Common Stock | -56,982 | $0.25 | $14k | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Michael Klichinsky Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative | -56,982 | $0.00 | $0 | 0 | Oct 8, 2025 |
| Oct 1, 2025 | Michael Klichinsky Chief Scientific Officer | SOpen-market sale Common Stock | -165,000 | $0.26 | $42k | 319,347 | Oct 3, 2025 |
| Oct 2, 2025 | Michael Klichinsky Chief Scientific Officer | SOpen-market sale Common Stock | -200,000 | $0.25 | $51k | 119,347 | Oct 3, 2025 |
| Oct 3, 2025 | Michael Klichinsky Chief Scientific Officer | SOpen-market sale Common Stock | -119,347 | $0.26 | $31k | 0 | Oct 3, 2025 |
| Jan 28, 2025 | Steven Kelly President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Jan 30, 2025 |
| Jan 28, 2025 | Michael Klichinsky Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +221,000 | $0.00 | $0 | 221,000 | Jan 30, 2025 |
| Oct 31, 2024 | Sohanya Roshan Cheng director | AGrant or award Stock Option (Right to Buy)derivative | +38,700 | $0.00 | $0 | 38,700 | Nov 1, 2024 |
| Jan 31, 2024 | Steven Kelly President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +438,000 | $0.00 | $0 | 438,000 | Feb 2, 2024 |
| Jan 31, 2024 | Michael Klichinsky Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +170,500 | $0.00 | $0 | 170,500 | Feb 2, 2024 |
| Jan 31, 2024 | Richard Steven Morris Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +170,500 | $0.00 | $0 | 170,500 | Feb 2, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Sohanya Roshan Chengdirector, officer
- Steven KellyPresident and CEO
- Michael KlichinskyChief Scientific Officer
- Richard Steven MorrisChief Financial Officer
Questions about CARM
Answered from the filings on this page, as of the latest one.
Are insiders buying CARM?
No. In the last 90 days no insider at Carisma Therapeutics Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CARM on the open market?
Michael Klichinsky (Chief Scientific Officer) sold $14k of CARM on Oct 7, 2025 and filed the Form 4 on Oct 8, 2025. InsiderTell scored 20 (weak).
How many insiders file Form 4 at Carisma Therapeutics Inc.?
4 people have filed a Form 4 at Carisma Therapeutics Inc., among them Sohanya Roshan Cheng (director and officer), Steven Kelly (President and CEO), Michael Klichinsky (Chief Scientific Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.